RAS protein activator-like 2 (RASAL2) initiates peritubular capillary rarefaction in hypoxic renal interstitial fibrosis

IF 6.4 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY
Yu Zhang , Yiqiong Yang , Xiuxiu Hu , Bizhen Wei , Qian Shen , Chuanbing Shi , Pingsheng Chen
{"title":"RAS protein activator-like 2 (RASAL2) initiates peritubular capillary rarefaction in hypoxic renal interstitial fibrosis","authors":"Yu Zhang ,&nbsp;Yiqiong Yang ,&nbsp;Xiuxiu Hu ,&nbsp;Bizhen Wei ,&nbsp;Qian Shen ,&nbsp;Chuanbing Shi ,&nbsp;Pingsheng Chen","doi":"10.1016/j.trsl.2024.03.003","DOIUrl":null,"url":null,"abstract":"<div><p>The progression of chronic kidney disease (CKD) often involves renal interstitial fibrosis (RIF) and subsequent loss of peritubular capillaries (PTCs), which enhances disease severity. Despite advancements in our understanding of fibrosis, effective interventions for reversing capillary loss remain elusive. Notably, RIF exhibits reduced capillary density, whereas renal cell carcinoma (RCC) shows robust angiogenesis under hypoxic conditions. Using RNA sequencing and bioinformatics, we identified differentially expressed genes (DEGs) in hypoxic human renal tubular epithelial cells (HK-2) and renal cancer cells (786-0). Analysis of altered Ras and PI3K/Akt pathways coupled with hub gene investigation revealed RAS protein activator-like 2 (RASAL2) as a key candidate. Subsequent <em>in vitro</em> and in vivo studies confirmed RASAL2′s early-stage response in RIF, which reduced with fibrosis progression. RASAL2 suppression in HK-2 cells enhanced angiogenesis, as evidenced by increased proliferation, migration, and branching of human umbilical vein endothelial cells (HUVECs) co-cultured with HK-2 cells. In mice, RASAL2 knockdown improved Vascular endothelial growth factor A (VEGFA) and Proliferating cell nuclear antigen (PCNA) levels in unilateral ureteral occlusion (UUO)-induced fibrosis (compared to wild type). Hypoxia-inducible factor 1 alpha (HIF-1α) emerged as a pivotal mediator, substantiated by chromatin immunoprecipitation (ChIP) sequencing, with its induction linked to activation. Hypoxia increased the production of RASAL2-enriched extracellular vesicles (EVs) derived from tubular cells, which were internalized by endothelial cells, contributing to the exacerbation of PTC loss. These findings underscore RASAL2′s role in mediating reduced angiogenesis in RIF and reveal a novel EV-mediated communication between hypoxic tubular- and endothelial cells, demonstrating a complex interplay between angiogenesis and fibrosis in CKD pathogenesis.</p></div>","PeriodicalId":23226,"journal":{"name":"Translational Research","volume":"269 ","pages":"Pages 14-30"},"PeriodicalIF":6.4000,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1931524424000471","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The progression of chronic kidney disease (CKD) often involves renal interstitial fibrosis (RIF) and subsequent loss of peritubular capillaries (PTCs), which enhances disease severity. Despite advancements in our understanding of fibrosis, effective interventions for reversing capillary loss remain elusive. Notably, RIF exhibits reduced capillary density, whereas renal cell carcinoma (RCC) shows robust angiogenesis under hypoxic conditions. Using RNA sequencing and bioinformatics, we identified differentially expressed genes (DEGs) in hypoxic human renal tubular epithelial cells (HK-2) and renal cancer cells (786-0). Analysis of altered Ras and PI3K/Akt pathways coupled with hub gene investigation revealed RAS protein activator-like 2 (RASAL2) as a key candidate. Subsequent in vitro and in vivo studies confirmed RASAL2′s early-stage response in RIF, which reduced with fibrosis progression. RASAL2 suppression in HK-2 cells enhanced angiogenesis, as evidenced by increased proliferation, migration, and branching of human umbilical vein endothelial cells (HUVECs) co-cultured with HK-2 cells. In mice, RASAL2 knockdown improved Vascular endothelial growth factor A (VEGFA) and Proliferating cell nuclear antigen (PCNA) levels in unilateral ureteral occlusion (UUO)-induced fibrosis (compared to wild type). Hypoxia-inducible factor 1 alpha (HIF-1α) emerged as a pivotal mediator, substantiated by chromatin immunoprecipitation (ChIP) sequencing, with its induction linked to activation. Hypoxia increased the production of RASAL2-enriched extracellular vesicles (EVs) derived from tubular cells, which were internalized by endothelial cells, contributing to the exacerbation of PTC loss. These findings underscore RASAL2′s role in mediating reduced angiogenesis in RIF and reveal a novel EV-mediated communication between hypoxic tubular- and endothelial cells, demonstrating a complex interplay between angiogenesis and fibrosis in CKD pathogenesis.

RAS 蛋白激活剂样 2 (RASAL2) 在缺氧性肾间质纤维化中引发管周毛细血管稀疏。
慢性肾脏病(CKD)的进展往往涉及肾间质纤维化(RIF)和随后的肾小管周围毛细血管(PTC)丧失,从而加重了疾病的严重程度。尽管我们对肾间质纤维化的认识有所进步,但逆转毛细血管损失的有效干预措施仍然遥遥无期。值得注意的是,RIF表现出毛细血管密度降低,而肾细胞癌(RCC)则在缺氧条件下表现出强劲的血管生成。利用 RNA 测序和生物信息学,我们确定了缺氧人肾小管上皮细胞(HK-2)和肾癌细胞(786-0)中的差异表达基因(DEGs)。通过对改变的 Ras 和 PI3K/Akt 通路的分析以及中心基因的调查,我们发现 RAS 蛋白激活剂样 2 (RASAL2) 是一个关键的候选基因。随后的体外和体内研究证实了 RASAL2 在 RIF 中的早期反应,这种反应随着纤维化的进展而减弱。抑制HK-2细胞中的RASAL2可增强血管生成,与HK-2细胞共培养的人脐静脉内皮细胞(HUVECs)的增殖、迁移和分支增加就是证明。在小鼠中,与野生型相比,RASAL2敲除可改善单侧输尿管闭塞(UUO)诱导的纤维化中血管内皮生长因子A(VEGFA)和增殖细胞核抗原(PCNA)的水平。染色质免疫沉淀(ChIP)测序证实,缺氧诱导因子1α(HIF-1α)是一个关键的介质,其诱导与活化有关。缺氧增加了来自肾小管细胞的富含 RASAL2 的细胞外囊泡 (EV) 的产生,这些囊泡被内皮细胞内化,导致 PTC 损失加剧。这些发现强调了RASAL2在RIF中介导血管生成减少的作用,并揭示了缺氧的肾小管细胞和内皮细胞之间由EV介导的新型交流,显示了血管生成和纤维化在CKD发病机制中复杂的相互作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Translational Research
Translational Research 医学-医学:内科
CiteScore
15.70
自引率
0.00%
发文量
195
审稿时长
14 days
期刊介绍: Translational Research (formerly The Journal of Laboratory and Clinical Medicine) delivers original investigations in the broad fields of laboratory, clinical, and public health research. Published monthly since 1915, it keeps readers up-to-date on significant biomedical research from all subspecialties of medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信